Support for returning to work after stem cell transplantation
Official title: Supportive Care Intervention Development to Address Employment Concerns After Allogeneic Hematopoietic Stem Cell Transplantation
Run by MGH Institute of Health Professions · NCT06494423 · Data updated 2026-11-12
This study is testing a program to help people who have had stem cell transplants get back to work and deal with any challenges they face in doing so.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 35 (estimated) |
| Sponsor | MGH Institute of Health Professions Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | July 31, 2024 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT06494423 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals who have received an allogeneic HSCT within the past six months and have expressed concerns about their ability to return to work.
✕Probably not a fit
Patients with acute psychiatric or cognitive conditions that hinder informed consent or compliance with study procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This feasibility study evaluates a Work Support (WorkS) intervention aimed at helping individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) to address employment challenges as they prepare to return to work. The study will assess the feasibility and acceptability of the WorkS intervention, as well as its preliminary effects on patient-reported outcomes such as return-to-work self-efficacy, work status, quality of life, and financial toxicity. Participants will be recruited from the MGH Cancer Center and will undergo assessments and appointments over a six-month period following their HSCT.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the ability of patients to return to work and enhance their overall quality of life post-transplant.
How similar studies have gone: While this approach is novel in the context of HSCT, similar interventions in other populations have shown promise in improving return-to-work outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received an allogeneic HSCT within the past six months to treat a hematological malignancy. * Screen positive for work-related concerns (i.e., responds "yes" to the question, "Are you concerned about your ability to return to work in the coming six months?") Exclusion Criteria: * Patients with acute psychiatric or cognitive conditions which the treating clinician believes prohibits informed consent or compliance with the study procedures * We will not enroll the following special populations: adults unable to consent, individuals not yet adults, pregnant women, and prisoners.
Where it's running
-
MGH Cancer Center
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Kathleen Lyons, ScD, OTR/L — MGH Institute of Health Professions
- Study coordinator: Kathleen Lyons, ScD, OTR/L
- Email: klyons2@mghihp.edu
- Phone: 614-643-5372
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant
This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.
-
Population PK-guided ATG Dosing in Haplo-HSCT
This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
-
Personalized ATG dosing in unrelated donor stem cell transplants
This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.
-
Hematologic cancer survivors after stem cell transplant try a personalized care plan
This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.
-
T-cell–guided letermovir stopping after allogeneic stem cell transplant
This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.